Global Non-Alcoholic Steatohepatitis (NASH) Market Valuation and Growth Prospects: $18.55 Billion by 2029

Uncover key drivers, emerging technologies, and competitive movements shaping the non-alcoholic steatohepatitis (nash) market from 2025–2034 with trusted insights from The Business Research Company

What Are The Future Growth Projections For The Non-Alcoholic Steatohepatitis (NASH) Market Size?

The non-alcoholic steatohepatitis (NASH) market has seen significant expansion in recent years. It is anticipated to increase from $4.5 billion in 2024 to $6.06 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 34.7%. This historic growth can be attributed to factors such as the rising prevalence of NASH, the obesity epidemic, enhanced awareness and diagnoses, evolving lifestyle and dietary patterns, and the development of healthcare infrastructure.

The market for non-alcoholic steatohepatitis (NASH) is projected to experience substantial expansion over the coming years. By 2029, it is forecast to reach $18.55 billion, demonstrating a compound annual growth rate (CAGR) of 32.3%. This expansion during the projection period is attributed to several factors, including advancements in NASH drug development, increasing NASH screening initiatives, rising healthcare expenditure, collaborative research efforts, and government support and regulations. Noteworthy trends anticipated in this period involve a focus on lifestyle interventions and patient education, enhanced collaboration in clinical research, regulatory advancements and pathway designations, and the integration of artificial intelligence in diagnosis and monitoring.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8805&type=smp

What Core Market Drivers Are Expanding The Non-Alcoholic Steatohepatitis (NASH) Industry?

The growing incidence of obesity is propelling the demand within the non-alcoholic steatohepatitis (NASH) market in the future. Obesity is characterized by an abnormal or excessive accumulation of fat, representing a significant health risk, and refers to a body weight surpassing what is considered healthy or standard for an individual’s height. Given the increased prevalence of non-alcoholic fatty liver disease, spurred by the growing obesity pandemic, NASH is poised to emerge as the leading cause of severe liver conditions in the coming decades, thus stimulating the need for NASH treatments and associated pharmaceuticals. For example, data from March 2024, provided by the World Health Organization (WHO), a UK-based international public health organization, indicated that in 2022, around 2.5 billion adults aged 18 and above were classified as overweight, with 890 million of these individuals specifically living with obesity. Consequently, the increasing prevalence of obesity cases is anticipated to fuel the expansion of the non-alcoholic steatohepatitis (NASH) market.

What Segment Insights Are Highlighted In The Non-Alcoholic Steatohepatitis (NASH) Market Report?

The non-alcoholic steatohepatitis (nash) market covered in this report is segmented –

1) By Type: Solid, Liquid

2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products

3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity

4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider

5) By Application: Oral, Parenteral

Subsegments:

1) By Solid: Tablets, Capsules, Other Solid Dosage Forms

2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms

Which Notable Trends Are Transforming The Non-Alcoholic Steatohepatitis (NASH) Market Outlook?

Leading companies in the non-alcoholic steatohepatitis (NASH) market are actively developing thyroid hormone receptor-beta (THR-beta) agonists with the aim of boosting liver metabolism, diminishing liver fat accumulation, and improving liver function. Thyroid hormone receptor-beta (THR-beta) agonists are chemical compounds that specifically activate the thyroid hormone receptor-beta subtype, a critical receptor involved in governing metabolism, growth, and development. For example, in March 2024, the Food and Drug Administration, a US-based regulatory authority, approved Rezdiffra (resmetirom), a thyroid hormone receptor-beta agonist, as the inaugural treatment for adults with noncirrhotic NASH who have moderate to advanced liver scarring (fibrosis). By precisely activating the THR-beta receptor, Rezdiffra contributes to the regulation of lipid metabolism, thereby leading to a reduction in intrahepatic triglycerides and overall liver fat accumulation.

Which Firms Are Driving Innovation Within The Non-Alcoholic Steatohepatitis (NASH) Market?

Major companies operating in the non-alcoholic steatohepatitis (NASH) market include NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Cadila Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-nash-global-market-report

What Regional Trends Are Shaping Growth In The Non-Alcoholic Steatohepatitis (NASH) Market?

North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2024. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=8805&type=smp

Browse Through More Reports Similar to the Global Non-Alcoholic Steatohepatitis (NASH) Market 2025, By The Business Research Company

Alcoholic Beverages Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/alcoholic-beverages-global-market-report

Grain Products Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/grain-products-global-market-report

Grain Farming Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/grain-farming-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795